X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Oncology Venture plans to advance Stenoparib into human clinical trials as a potential therapy for COVID-19. Stenoparib (2X-121) is a novel small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase, a key DNA damage repair enzyme active in cancer cells.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.
Lead Product(s): Stenoparib
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: 2X Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 13, 2020
Details:
Oncology Venture has entered a definitive agreement, out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development.
Lead Product(s): Cisplatin
Therapeutic Area: Oncology Product Name: LiPlaCis
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Smerud Medical Research
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 29, 2020
Details:
Oncology Venture has acquired the remaining 37% ownership in its priority Dovitinib program from investor Sass & Larsen ApS. As a result of the transaction, the Company now has full control of its most advanced pipeline program.
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sass & Larsen ApS
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
Oncology Venture will test the ability of 2X-121 to block the infection of cells and replication of carnivorous in pre-clinical Studies at Pathogen & Microbiome Institute.
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Pathogen and Microbiome Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
